New combo targets lung cancer brain tumors in 60-patient trial
NCT ID NCT07365410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a higher dose of furmonertinib alone works better than a standard dose combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain. About 60 adults who have not had prior treatment will be enrolled. The goal is to see which approach delays cancer growth and is safer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Can a 3D camera make brain radiation safer and more precise?
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Pinpoint radiation may spare the brain in lung cancer that spreads
- Spinal fluid DNA test could personalize brain cancer therapy